Jasper Therapeutics, Inc. expected to post a loss of 35 cents a share - Earnings Preview

Jasper Therapeutics

07/08/2026 16:01

Jasper Therapeutics, Inc. JSPR.OQ JSPR.O is expected to  show no change in quarterly revenue when it reports  results on August 11 (estimated) for the period ending June 30 2026

​LSEG's mean analyst estimate for Jasper Therapeutics, Inc. is for a loss of 35 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Jasper Therapeutics, Inc. is $6.50, about 906% above its last closing price of $0.65
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.49
-0.49
-0.04
Beat
91.8
Dec. 31 2026
-1.20
-0.74
-0.32
Beat
57
Sep. 30 2025
-1.25
-1.21
-1.25
Missed
-2.9​
Jun. 30 2025
-1.34
-1.33
-1.74
Missed
-31.2
​​Mar. 31 2025
-1.34
-1.31
-1.41
Missed
-7.4
Dec. 31 2024
-1.23
-1.23
-1.62
Missed
-31.7​
Sep. 30 2024
-1.08
-1.07
-1.24
Missed
-15.7
Jun. 30 2024
-1.08
-1.09
-0.97
Beat
10.9
This summary was machine generated August 7 at 15:01 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)